The role of LEPR, PPARG and PPARGC1A genes polymorphisms in the development of metabolic disorders in patients with vibration diseases

Cover Page

Cite item

Full Text

Abstract

Introduction. Patients with vibration disease (VD) often have obesity and metabolic syndrome (MS), which increase the risk of developing type 2 diabetes, hypertension, and other conditions predisposing to a decrease in the quality and longevity of life. Genetic predisposition, overnutrition, environmental factors, including industrial ones, and others are factors influencing the formation of MS. 

The aim of the study is to identify associations between polymorphisms of the LEPR, PPARG and PPARGC1A genes, metabolic syndrome and obesity in VD patients caused by exposure to local vibration and the combined effects of local and general vibration. 

Material and methods. We examined 248 VD male patients exposed to local vibration and the combined impact of the local and general vibration. We have identified a subgroup of MS and obesity cases. The distribution of genotypes of the LEPR, PPARG and PPARGC1A genes in groups was studied. 

Results. In the group of VD and MS patients exposed to the combined effect of local and general vibration, the Gln/Gln genotype of the Arg223Gln polymorphic locus of the LEPR gene was less common, and the Arg / Gln genotype in MS cases was detected more often than in patients without it. Among patients with VD caused by exposure to local vibration with a waist circumference of more than 102 cm, the Gly / Ser genotype of the Gly482Ser polymorphism of the PPARGC1A gene was more common than among those with lower values of this indicator. 

Conclusion. In patients with VD caused by combined exposure to local and general vibration, the Gln/Gln genotype carrier of the Arg223Gln polymorphism of the LEPR gene may play a protective role in the formation of MS. Among individuals with VD caused by exposure to local vibration, carriers of the heterozygous genotype of the Gly482Ser polymorphism of the PPARGC1A gene may have a predisposition to the development of obesity. The obtained results are preliminary and require further research.

Contribution:

Masnavieva L.B. — concept and design of the study, collection and processing of material, statistical processing, writing and editing the text;

Chistova N.P. — collection and processing of material;

Naumova O.V. — collection and processing of material;

Kudaeva I.V. — approval of the final version of the article.

Conflict of interest. The authors declare no conflict of interest.

Acknowledgment. The study had no sponsorship.

About the authors

Liudmila B. Masnavieva

East-Siberian Institute of Medical and Ecological Research

Author for correspondence.
Email: masnavieva_luda@mail.ru
ORCID iD: 0000-0002-1400-6345

MD, PhD, DSci., senior researcher, laboratory of immunological, biochemical, molecular and genetic researches, East-Siberian
Institute of Medical and Ecological Research.

e-mail: Masnavieva_Luda@mail.ru

Russian Federation

Nadezhda P. Chistova

East-Siberian Institute of Medical and Ecological Research

Email: noemail@neicon.ru
ORCID iD: 0000-0002-1206-6379
Russian Federation

Olga V. Naumova

East-Siberian Institute of Medical and Ecological Research

Email: noemail@neicon.ru
ORCID iD: 0000-0002-5353-2268
Russian Federation

Irina V. Kudaeva

East-Siberian Institute of Medical and Ecological Research

Email: noemail@neicon.ru
ORCID iD: 0000-0002-5608-0818
Russian Federation

References

  1. Balanova Yu.A., Shal’nova S.A., Deev A.D., Imaeva A.E., Kontsevaya A.V., Muromtseva G.A., et al. Obesity in Russian population – prevalence and association with the non-communicable diseases risk factors. Rossiyskiy kardiologicheskiy zhurnal. 2018; 23(6): 123–30. https://doi.org/10.15829/1560-4071-2018-6-123-130 (in Russian)
  2. Recommendations of experts of Russian Scientific Society of Cardiologists on diagnosis and treatment of metabolic syndrome. Prakticheskaya meditsina. 2010; (5): 81–101. (in Russian)
  3. Klyaritskaya I.L., Maksimova E.V. Obesity. Krymskiy terapevticheskiy zhurnal. 2009; (2): 9–19. (in Russian)
  4. Rotar’ O.P., Libis R.A., Isaeva E.N., Erina A.M., Shavshin D.A., Moguchaya E.V., et al. Metabolic syndrome prevalence in Russian cities. Rossiyskiy kardiologicheskiy zhurnal. 2012; 17(2): 55–62. (in Russian)
  5. Mamedov M.N., Suslonova N.V., Lisenkova I.Yu., Tokareva Z.N., Evdokimova A.A., Shalnova S.A., et al. Metabolic syndrome prevalence in Russia: Preliminary results of a cross-sectional population study. Diabet. Vasc. Dis. Res. 2007; 4(1): 46–7.
  6. Kuz’mina O.Yu. Clinical and epidemiological features of metabolic syndrome in patients with occupational diseases. Mezhdunarodnyy endokrinologicheskiy zhurnal. 2011; (4): 154–60. (in Russian)
  7. Panacheva L.A., Platonova E.A., Kuznetsova G.V. Prevalence and clinical manifestations of metabolic syndrome in vibration disease. Meditsina truda i promyshlennaya ekologiya. 2011; (10): 36–9. (in Russian)
  8. Reznik L.A., Isaeva A.S. Genetic aspects of obesity and metabolic disorders associated with him. Norwegian Journal of Development of the International Science. 2020; (40–2): 38–43. (in Russian)
  9. Sikhaeva N.S., Dzharmukhanov Zh.M., Zholdybaeva E.V., Ramankulov E.M. The occurrence frequencies of allele polymorphisms in ADRB2, FABP2, PPARG, FTO, ADRB3 and APOA2 genes among the indigenous population of Kazakhstan. Molekulyarnaya i prikladnaya genetika. 2015; (19): 59–63. (in Russian)
  10. Cheurfa N., Reis A.F., Dubois-Laforgue D., Bellanné-Chantelot C., Timsit J., Velho G. The Gly482Ser polymorphism in the peroxisome proliferator-activated receptor-gamma coactivator-1 gene is associated with hypertension in type 2 diabetic men. Diabetologia. 2004; 47(11): 1980–3. https://doi.org/10.1007/s00125-004-1567-4
  11. Kravchenko N.A., Yarmysh N.V. Role of PPARS and their isoforms in metabolic disorders related to insulin resistance and diabetes. Cytol. Genet. 2011; 45(3): 191–9. https://doi.org/10.3103/S0095452711030042
  12. Li Q., Chen R., Bie L., Zhao D., Huang C., Hong J. Association of the variants in the PPARG gene and serum lipid levels: a meta-analysis of 74 studies. J. Cell. Mol. Med. 2015; 19(1): 198–209. https://doi.org/10.1111/jcmm.12417
  13. Uspenskiy Yu.P., Petrenko Yu.V., Gulunov Z.Kh., Shaporova N.L., Fominykh Yu.A., Niyazov R.M. Metabolic syndrome [Metabolicheskiy sindrom]. St. Perersburg; 2017. (in Russian)
  14. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – The evidence report. Obes. Res. 1998; 6(Suppl. 2): 51S-209S.
  15. Lean M.E., Han T.S., Morrison C.E. Waist circumference as a measure for indicating need for weight management. BMJ. 1995; 311(6998): 158–61. https://doi.org/10.1136/bmj.311.6998.158
  16. Belik V.P., Kudaeva I.V., Masnavieva L.B. The adaptation of methods for isolating DNA from frozen blood. Meditsinskiy alfavit. Sovremennaya laboratoriya. 2014; 1(2): 36–8. (in Russian)
  17. Ben Ali S., Kallel A., Sediri Y., Ftouhi B., Feki M., Slimene H., et al. LEPR p.Q223R Polymorphism influences plasma leptin levels and body mass index in Tunisian obese patients. Arch. Med. Res. 2009; 40(3): 186–90. https://doi.org/10.1016/j.arcmed.2009.02.008
  18. Deeb S.S., Fajas L., Nemoto M., Pihlajamäki J., Mykkänen L., Kuusisto J., et al. A Pro12Ala substitution in PPARg2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 1998; 20(3): 284–7. https://doi.org/10.1038/3099
  19. Finck B.N., Kelly D.P. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation. 2007; 115(19): 2540–8. https://doi.org/10.1161/CIRCULATIONAHA.107.670588
  20. Li Y.Y., Wang H., Yang X.X., Wu J.J., Geng H.Y., Kim H.J., et al. LEPR gene Gln223Arg polymorphism and type 2 diabetes mellitus: a meta-analysis of 3,367 subjects. Oncotarget. 2017; 8(37): 61927–34. https://doi.org/10.18632/oncotarget.18720
  21. Tkhakushinov R.A. Lysenkov S.P., Tuguz A.R., Smol’kov I.V., Shumilov D.S., Muzhenya D.V. LEPR (Arg223Gln), FTO (A23525T), ADRB3 (Trp64Arg) and PPARG (Pro12Ala) gene polymorphisms under normal and excess body weight. Vestnik Adygeyskogo gosudarstvennogo universiteta. Seriya 4: Estestvenno-matematicheskie i tekhnicheskie nauki. 2016; (4): 80–7. (in Russian)
  22. Constantin A., Costache G., Sima A.V., Glavce C.S., Vladica M., Popov D.L. Leptin G-2548A and leptin receptor Q223R gene polymorphisms are not associated with obesity in Romanian subjects. Biochem. Biophys. Res. Commun. 2010; 391(1): 282–6. https://doi.org/10.1016/j.bbrc.2009.11.050
  23. Quinton N.D., Lee A.J., Ross R.J., Eastell R., Blakemore A.I. A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Hum. Genet. 2001; 108(3): 233–6. https://doi.org/10.1007/s004390100468
  24. Babanov S.A., Vakurova N.V., Azovskova T.A. Vibration Disease. Optimization of Diagnostic and Therapeutic Measures [Vibratsionnaya bolezn’. optimizatsiya diagnosticheskikh i lechebnykh meropriyatiy]. Samara; 2012. (in Russian)
  25. Solntseva A.V., Sukalo A.V., Zagrebaeva O.Yu., Krum A.V. Neuroendocrine regulation of obesity. Zdravookhranenie (Minsk). 2014; (11): 33–6. (in Russian)
  26. Drozdovska S.B., Borovik O.A., Docenko V.E., Ilyin V.N Peroxisome proliferator-activated receptor gamma genes polymorphism (PPARG) as a marker for predisposition to sports. Pedagogika, psihologiya i mediko-biologicheskie problemy fizicheskogo vospitaniya i sporta. 2012; (4): 52-57. (in Russian)
  27. Masud S., Ye S., SAS Group. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J. Med. Genet. 2003; 40(10): 773–80. https://doi.org/10.1136/jmg.40.10.773
  28. Csép K., Szigeti E., Vitai M., Korányi L. The PPARGC1A – Gly482Ser polymorphism (rs8192678) and the metabolic syndrome in a central Romanian population. Acta Endocrinol. (Buchar.). 2017; 13(2): 161–7. https://doi.org/10.4183/aeb.2017.161
  29. Mercado M.V., Guzmán-Ornelas M.O., Corona Meraz F.I., Ríos-Ibarra C.P., Reyes-Serratos E.A., Castro-Albarran J., et al. The 482Ser of PPARGC1A and 12Pro of PPARG2 alleles are associated with reduction of metabolic risk factors even obesity in a Mexican-Mestizo population. Biomed. Res. Int. 2015; 2015: 285491. https://doi.org/10.1155/2015/285491
  30. Vorob’eva V.V., Shabanov P.D. Stressogenic exposure of local vibration to energetic metabolism of the heart, liver and kidney of rats. Rossiyskiy fiziologicheskiy zhurnal im. I.M. Sechenova. 2012; 98(2): 293–9. (in Russian)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Masnavieva L.B., Chistova N.P., Naumova O.V., Kudaeva I.V.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 37884 от 02.10.2009.